Neuromuscular Research Funding Announcements From Jesse’s Journey and Muscular Dystrophy Canada
The NMD4C is excited to share recent grant funding announcements from two of our partners, Jesse’s Journey and Muscular Dystrophy Canada. The network is incredibly fortunate to be able to collaborate with these incredible organizations, and it is our pleasure to recognize the contributions of each towards helping to fund neuromuscular research.
Jesse’s Journey
Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, will grant $1.7M toward four promising research projects this year – the largest annual amount in its 26-year history.
Newly funded projects in 2021 include:
Dr. Niclas Bengtsson: Development of gene regulatory cassettes that enable safe- and efficient in vivo dystrophin gene-editing in muscle stem cells.
Dr. Natasha Chang: Inducing stress granule formation in muscle stem cells to treat DMD.
Dr. Ronald Cohn: Simultaneous DMD gene editing and upregulation to restore protective levels of full-length dystrophin in the treatment of DMD duplication mutations.
Dr. Sachiko Sato: Development of a Monosaccharide Therapy Using N-Acetylglucosamine to Mitigate Duchenne Muscular Dystrophy.
The growth in scientific funding interest is encouraging for the community because it means there is an increasing commitment to Duchenne science and drug discovery, bringing hope and progress towards prevention, treatment, and ultimately – a cure.
Read the full press release from Jesse’s Journey here!
Muscular Dystrophy Canada
Muscular Dystrophy Canada (MDC) has announced an investment of $400,000 to fund seven new research projects in 2021 through the MDC Neuromuscular Disorder (NMD) Research Grant Competition, a dedicated Canadian source of funding for neuromuscular research. MDC will also invest in an international, collaborative, $1.15 million, research project through the European Joint Programme on Rare Diseases (EJP RD).
The 2020-2021 research grant recipients are:
Dr. Alex Parker: A Pharmacogenetic Pipeline for Charcot-Marie-Tooth Disease
Dr. Colin Crist: Promoting Muscle Repair by Pharmacological Inhibition of eIF2a Dephosphorylation
Dr. Mohamed Chahine: Human iPSC-derived Neurons as a Model of Congenital Myotonic Dystrophy Type 1
Dr. Nadine Wiper-Bergeron: Improving Myoblast Transplantation Outcomes via Pharmacological Reprogramming
Dr. Nicolas Dumont: Targeting Defective Stem Cells in a Preclinical Model of Myotonic Dystrophy Type 1
Dr. Rima Al-Awar (EJPRD/CIHR Co-funded): Safety and Efficacy of a Possible Epigenetic Therapy for Facioscapulohumeral Muscular Dystrophy
Dr. Toshifumi Yokota: Enhancing the Efficacy of Antisense Oligonucleotide Therapy for Facioscapulohumeral Muscular Dystrophy
Read the full press release from Muscular Dystrophy Canada here!
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.